VLP stands for virus-like particles. Virus-like particles are molecules that mimic viruses but are not infectious. They are a very effective way of creating vaccines against diseases such as human ...
Wataru Akahata, CEO of VLP Therapeutics Japan LLC, thinks he can help provide a solution to the challenge of securing COVID-19 vaccines for billions of people — the development of a second-generation ...
Serum Institute of India (SII) has announced it has partnered with UK biotech company, Spybiotech, a spin-off of the University of Oxford, to develop a COVID-19 virus-like-particle (VLP)-based vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results